Regeneron Pharmaceuticals Inc (REGN)

Net profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	3,953,600	3,991,100	4,299,000	4,182,700	4,338,400	5,370,300	5,686,800	7,933,600	8,075,300	6,995,500	6,205,400	4,003,800	3,513,200	3,156,000	2,983,500	2,279,300	2,115,800	2,144,200	2,069,300	2,427,600
Revenue (ttm)	US$ in thousands	13,044,200	13,025,200	12,601,200	12,306,100	12,113,500	13,654,100	14,171,800	16,451,800	16,014,400	13,499,700	12,328,800	9,147,000	8,455,000	8,201,600	7,974,500	7,957,900	7,839,900	7,598,200	7,213,600	6,889,000
Net profit margin		30.31%	30.64%	34.12%	33.99%	35.81%	39.33%	40.13%	48.22%	50.43%	51.82%	50.33%	43.77%	41.55%	38.48%	37.41%	28.64%	26.99%	28.22%	28.69%	35.24%

December 31, 2023 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $3,953,600K ÷ $13,044,200K
= 30.31%

Regeneron Pharmaceuticals, Inc. has maintained a relatively stable net profit margin over the past eight quarters, ranging from 30.14% to 48.06%. The net profit margin indicates the company's efficiency in managing its expenses relative to its revenue.

The downward trend observed from Q4 2022 (35.64%) to Q1 2023 (33.81%) suggests a slight decrease in profitability during this period. However, the company's ability to maintain a net profit margin above 30% throughout demonstrates consistent profitability levels.

The sharp increase in net profit margin from Q1 2022 (48.06%) to Q2 2022 (39.97%) followed by a subsequent decrease in Q3 2022 (39.17%) and Q4 2022 (35.64%) indicates some volatility in the company's profitability during that period.

Overall, while there have been fluctuations in Regeneron Pharmaceuticals, Inc.'s net profit margin over the quarters analyzed, the company has generally exhibited strong profitability, indicating effective cost management and potential for sustained financial performance.